Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs
Authors:
- 1 January 2011
- journal article
- review article
- Vol. 3 (2) , 166-179
Abstract
Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Recently, their use has been clinically validated in cancer patients resulting in the approval of two HDAC inhibitors, vorinostat and depsipetide, by the FDA. Also, clinical trials of several HDAC inhibitors for use as anti-cancer drugs (alone or in combination with other anti-cancer therapeutics) are ongoing. However, the molecular mechanisms underlying the response to HDAC inhibitors in cancer patients are not fully understood. In this review, we summarize our understanding of the molecular and biological events that underpin the anticancer effects of HDAC inhibitors and the outcomes of recent clinical trials involving these drugs.Keywords
This publication has 100 references indexed in Scilit:
- Epigenetic control of skull morphogenesis by histone deacetylase 8Genes & Development, 2009
- Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse modelsJournal of Experimental Medicine, 2008
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Investigational New Drugs, 2008
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapyCancer Letters, 2008
- Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop NormallyMolecular and Cellular Biology, 2008
- Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractilityGenes & Development, 2007
- Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodentsBritish Journal of Pharmacology, 2007
- Negative and Positive Regulation of Gene Expression by Mouse Histone Deacetylase 1Molecular and Cellular Biology, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate CancerThe Prostate, 2004